The global Hepatocyte Growth Factor market size was valued at US$ 77.9 million in 2024 and is forecast to a readjusted size of USD 463 million by 2031 with a CAGR of 29.3% during review period.
Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.
Asia Pacific will be the largest region of Hepatocyte Growth Factor, which will occupy about 60% market share in 2030. North America will be the second largest market with the consumption market share of 25% in 2030. ViroMed, AnGes MG, M3 Biotechnology, AVEO Pharmaceuticals, Molecular Partners and Yooyoung Pharm are the major manufacturers of industry.
This report is a detailed and comprehensive analysis for global Hepatocyte Growth Factor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Hepatocyte Growth Factor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Hepatocyte Growth Factor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Hepatocyte Growth Factor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Hepatocyte Growth Factor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hepatocyte Growth Factor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hepatocyte Growth Factor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ViroMed, AnGes MG, M3 Biotechnology, AVEO Pharmaceuticals, Molecular Partners, Yooyoung Pharm, F-star, Galaxy Biotech, Kringle Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Hepatocyte Growth Factor market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Phase III (Ongoing)
Phase II (Approved)
Phase II (Ongoing)
Phase 1
Preclinical
麻豆原创 segment by Application
Oncology
Cardiovascular
Central Nervous System
Hematological Disorders
Others
Major players covered
ViroMed
AnGes MG
M3 Biotechnology
AVEO Pharmaceuticals
Molecular Partners
Yooyoung Pharm
F-star
Galaxy Biotech
Kringle Pharma
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hepatocyte Growth Factor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Hepatocyte Growth Factor, with price, sales quantity, revenue, and global market share of Hepatocyte Growth Factor from 2020 to 2025.
Chapter 3, the Hepatocyte Growth Factor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hepatocyte Growth Factor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Hepatocyte Growth Factor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Hepatocyte Growth Factor.
Chapter 14 and 15, to describe Hepatocyte Growth Factor sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Hepatocyte Growth Factor Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Phase III (Ongoing)
1.3.3 Phase II (Approved)
1.3.4 Phase II (Ongoing)
1.3.5 Phase 1
1.3.6 Preclinical
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Hepatocyte Growth Factor Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Oncology
1.4.3 Cardiovascular
1.4.4 Central Nervous System
1.4.5 Hematological Disorders
1.4.6 Others
1.5 Global Hepatocyte Growth Factor 麻豆原创 Size & Forecast
1.5.1 Global Hepatocyte Growth Factor Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Hepatocyte Growth Factor Sales Quantity (2020-2031)
1.5.3 Global Hepatocyte Growth Factor Average Price (2020-2031)
2 Manufacturers Profiles
2.1 ViroMed
2.1.1 ViroMed Details
2.1.2 ViroMed Major Business
2.1.3 ViroMed Hepatocyte Growth Factor Product and Services
2.1.4 ViroMed Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 ViroMed Recent Developments/Updates
2.2 AnGes MG
2.2.1 AnGes MG Details
2.2.2 AnGes MG Major Business
2.2.3 AnGes MG Hepatocyte Growth Factor Product and Services
2.2.4 AnGes MG Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 AnGes MG Recent Developments/Updates
2.3 M3 Biotechnology
2.3.1 M3 Biotechnology Details
2.3.2 M3 Biotechnology Major Business
2.3.3 M3 Biotechnology Hepatocyte Growth Factor Product and Services
2.3.4 M3 Biotechnology Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 M3 Biotechnology Recent Developments/Updates
2.4 AVEO Pharmaceuticals
2.4.1 AVEO Pharmaceuticals Details
2.4.2 AVEO Pharmaceuticals Major Business
2.4.3 AVEO Pharmaceuticals Hepatocyte Growth Factor Product and Services
2.4.4 AVEO Pharmaceuticals Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 AVEO Pharmaceuticals Recent Developments/Updates
2.5 Molecular Partners
2.5.1 Molecular Partners Details
2.5.2 Molecular Partners Major Business
2.5.3 Molecular Partners Hepatocyte Growth Factor Product and Services
2.5.4 Molecular Partners Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Molecular Partners Recent Developments/Updates
2.6 Yooyoung Pharm
2.6.1 Yooyoung Pharm Details
2.6.2 Yooyoung Pharm Major Business
2.6.3 Yooyoung Pharm Hepatocyte Growth Factor Product and Services
2.6.4 Yooyoung Pharm Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Yooyoung Pharm Recent Developments/Updates
2.7 F-star
2.7.1 F-star Details
2.7.2 F-star Major Business
2.7.3 F-star Hepatocyte Growth Factor Product and Services
2.7.4 F-star Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 F-star Recent Developments/Updates
2.8 Galaxy Biotech
2.8.1 Galaxy Biotech Details
2.8.2 Galaxy Biotech Major Business
2.8.3 Galaxy Biotech Hepatocyte Growth Factor Product and Services
2.8.4 Galaxy Biotech Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Galaxy Biotech Recent Developments/Updates
2.9 Kringle Pharma
2.9.1 Kringle Pharma Details
2.9.2 Kringle Pharma Major Business
2.9.3 Kringle Pharma Hepatocyte Growth Factor Product and Services
2.9.4 Kringle Pharma Hepatocyte Growth Factor Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Kringle Pharma Recent Developments/Updates
3 Competitive Environment: Hepatocyte Growth Factor by Manufacturer
3.1 Global Hepatocyte Growth Factor Sales Quantity by Manufacturer (2020-2025)
3.2 Global Hepatocyte Growth Factor Revenue by Manufacturer (2020-2025)
3.3 Global Hepatocyte Growth Factor Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Hepatocyte Growth Factor by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Hepatocyte Growth Factor Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Hepatocyte Growth Factor Manufacturer 麻豆原创 Share in 2024
3.5 Hepatocyte Growth Factor 麻豆原创: Overall Company Footprint Analysis
3.5.1 Hepatocyte Growth Factor 麻豆原创: Region Footprint
3.5.2 Hepatocyte Growth Factor 麻豆原创: Company Product Type Footprint
3.5.3 Hepatocyte Growth Factor 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Hepatocyte Growth Factor 麻豆原创 Size by Region
4.1.1 Global Hepatocyte Growth Factor Sales Quantity by Region (2020-2031)
4.1.2 Global Hepatocyte Growth Factor Consumption Value by Region (2020-2031)
4.1.3 Global Hepatocyte Growth Factor Average Price by Region (2020-2031)
4.2 North America Hepatocyte Growth Factor Consumption Value (2020-2031)
4.3 Europe Hepatocyte Growth Factor Consumption Value (2020-2031)
4.4 Asia-Pacific Hepatocyte Growth Factor Consumption Value (2020-2031)
4.5 South America Hepatocyte Growth Factor Consumption Value (2020-2031)
4.6 Middle East & Africa Hepatocyte Growth Factor Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Hepatocyte Growth Factor Sales Quantity by Type (2020-2031)
5.2 Global Hepatocyte Growth Factor Consumption Value by Type (2020-2031)
5.3 Global Hepatocyte Growth Factor Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Hepatocyte Growth Factor Sales Quantity by Application (2020-2031)
6.2 Global Hepatocyte Growth Factor Consumption Value by Application (2020-2031)
6.3 Global Hepatocyte Growth Factor Average Price by Application (2020-2031)
7 North America
7.1 North America Hepatocyte Growth Factor Sales Quantity by Type (2020-2031)
7.2 North America Hepatocyte Growth Factor Sales Quantity by Application (2020-2031)
7.3 North America Hepatocyte Growth Factor 麻豆原创 Size by Country
7.3.1 North America Hepatocyte Growth Factor Sales Quantity by Country (2020-2031)
7.3.2 North America Hepatocyte Growth Factor Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Hepatocyte Growth Factor Sales Quantity by Type (2020-2031)
8.2 Europe Hepatocyte Growth Factor Sales Quantity by Application (2020-2031)
8.3 Europe Hepatocyte Growth Factor 麻豆原创 Size by Country
8.3.1 Europe Hepatocyte Growth Factor Sales Quantity by Country (2020-2031)
8.3.2 Europe Hepatocyte Growth Factor Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Hepatocyte Growth Factor Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Hepatocyte Growth Factor Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Hepatocyte Growth Factor 麻豆原创 Size by Region
9.3.1 Asia-Pacific Hepatocyte Growth Factor Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Hepatocyte Growth Factor Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Hepatocyte Growth Factor Sales Quantity by Type (2020-2031)
10.2 South America Hepatocyte Growth Factor Sales Quantity by Application (2020-2031)
10.3 South America Hepatocyte Growth Factor 麻豆原创 Size by Country
10.3.1 South America Hepatocyte Growth Factor Sales Quantity by Country (2020-2031)
10.3.2 South America Hepatocyte Growth Factor Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Hepatocyte Growth Factor Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Hepatocyte Growth Factor Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Hepatocyte Growth Factor 麻豆原创 Size by Country
11.3.1 Middle East & Africa Hepatocyte Growth Factor Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Hepatocyte Growth Factor Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Hepatocyte Growth Factor 麻豆原创 Drivers
12.2 Hepatocyte Growth Factor 麻豆原创 Restraints
12.3 Hepatocyte Growth Factor Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Hepatocyte Growth Factor and Key Manufacturers
13.2 Manufacturing Costs Percentage of Hepatocyte Growth Factor
13.3 Hepatocyte Growth Factor Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Hepatocyte Growth Factor Typical Distributors
14.3 Hepatocyte Growth Factor Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
ViroMed
AnGes MG
M3 Biotechnology
AVEO Pharmaceuticals
Molecular Partners
Yooyoung Pharm
F-star
Galaxy Biotech
Kringle Pharma
听
听
*If Applicable.
